Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (ICH E2A)

E2A_Full_Thumbnail.jpg
E2A_Full_Thumbnail.jpg

Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (ICH E2A)

$199.00

To purchase access for your team, or if you have any questions, email us at info@clinicalpathwaysresearch.com.

Course outline HERE

Add To Cart

INTERACTIVE DEMO AVAILABLE BELOW

This course covers the international Guideline ICH E2A, which relates to Clinical Safety Data Management. Sections include a review of ICH and an introduction to ICH E2A; Definitions and Terminology related to the clinical safety experience; standards for expedited reporting; reporting time frame, the procedures for reporting, managing blinded therapy cases, miscellaneous issues, and informing Ethics Committees and Investigators; and Quality Management Systems.

This course can be used alone or as part of the full curriculum; for more information refer to the additional information below.

Course Length: 45 minutes

INCLUDES:

  • Unlimited access to the content for 45 days from your initial day of purchase.

  • Certificate of completion

  • Case Studies

  • Post-Assessment

  • Knowledge Checks

LEARNING OBJECTIVES

  1. Apply critical thinking techniques for effective implementation of the ICH E2A guidelines.

  2. Reflect on how the ICH E2A global guideline affects your role in clinical research.

  3. Discuss challenges and opportunities in implementing the ICH E2A guideline.

AUDIENCE

All clinical research personnel

INTERACTIVE DEMO:

 

ONBOARDING OR ANNUAL REVIEW CURRICULUM

This course can be used alone or as part of the full curriculum, including:

  1. GCP Training: ICH E6(R2) - Available HERE

  2. Good Documentation Practices and ALCOA-C - Available HERE

  3. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (ICH E2A) - Available HERE

  4. Structure and Content of Clinical Study Reports (ICH E3) - Available HERE

  5. Overview of 21 CFR 312 Investigational New Drug Application (IND) and 21 CFR 314 Application for FDA Approval to Market a New Drug (NDA) - Available HERE

  6. Overview of 21 CFR Part 50 Human Subject Protection and 21 CFR Part 56 IRB/IEC - Available HERE

  7. Overview of 21 CFR Part 11 Electronic Data / Signatures & 21 CFR Part 54 Financial Disclosure - HERE